AMP-109 | Search

临床试验

计划入组 50 人 · 首次发布于 2024 年 11 月 29 日

尚未招募

NCT06614530

Effectiveness of Chilipad in Enhancing Sleep Quality &amp; Wellbeing

计划入组 120 人 · 首次发布于 2024 年 9 月 26 日

已完成

NCT05021679

AMP Step Wedge Trial

计划入组 16,676 人 · 首次发布于 2021 年 8 月 25 日

药物

查看全部 3721 →

Biotech

Investigational

AMP-101

AMP-303

AMP-423

机构

查看全部 61 →

NATIONAL INSTITUTE OF DISEASES OF THE CHEST AND HOSPITAL

Bangladesh

Calosyn Pharma, Inc.

United States

Seres Therapeutics

United States

资讯

查看全部 2255 →

8个月前

Amphastar Pharmaceuticals Advances Proprietary Pipeline with Novel Eye Drop and Cancer Therapies

8个月前

Amphastar Secures Exclusive Rights to Synthetic ACTH Analog AMP-110 in $158 Million Deal

去年

临床试验

ReceptIVFity &amp; Immunology in ART

Effectiveness of Chilipad in Enhancing Sleep Quality &amp; Wellbeing

AMP Step Wedge Trial

药物

AMP-101

AMP-303

AMP-423

机构

NATIONAL INSTITUTE OF DISEASES OF THE CHEST AND HOSPITAL

Calosyn Pharma, Inc.

Seres Therapeutics

资讯

Amphastar Pharmaceuticals Advances Proprietary Pipeline with Novel Eye Drop and Cancer Therapies

Amphastar Secures Exclusive Rights to Synthetic ACTH Analog AMP-110 in $158 Million Deal

DT-109: Novel Glycine-Based Compound Shows Dual Efficacy Against Atherosclerosis and MASH

临床试验

ReceptIVFity &amp;amp; Immunology in ART

Effectiveness of Chilipad in Enhancing Sleep Quality &amp;amp; Wellbeing

AMP Step Wedge Trial

药物

AMP-101

AMP-303

AMP-423

机构

NATIONAL INSTITUTE OF DISEASES OF THE CHEST AND HOSPITAL

Calosyn Pharma, Inc.

Seres Therapeutics

资讯

Amphastar Pharmaceuticals Advances Proprietary Pipeline with Novel Eye Drop and Cancer Therapies

Amphastar Secures Exclusive Rights to Synthetic ACTH Analog AMP-110 in $158 Million Deal

DT-109: Novel Glycine-Based Compound Shows Dual Efficacy Against Atherosclerosis and MASH

ReceptIVFity & Immunology in ART

Effectiveness of Chilipad in Enhancing Sleep Quality & Wellbeing